Printer Friendly

ITALIAN SCIENTISTS REPORT PRELIMINARY RESULTS FROM THYMOSIN ALPHA 1 HEPATITIS B CLINICAL TRIAL

 ITALIAN SCIENTISTS REPORT PRELIMINARY RESULTS FROM THYMOSIN ALPHA 1
 HEPATITIS B CLINICAL TRIAL
 WASHINGTON, April 7 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), today issued the following:
 Preliminary results of a randomized study treating 14 chronic hepatitis B patients with Thymosin alpha 1 or interferon were presented at the Second International Meeting on Therapies for Diseases of the Liver by Drs. I. Rezakovic, L. Mondazzi, C. Savaglia, L. Asti, and G. Ideo of the Niguarda Ca Granda Hospital in Milan. Patients were randomized and treated with one of the two drugs for six months with ongoing follow-up for four to 15 months. Six of the seven (86 percent) Thymosin alpha 1 treated patients lost the hepatitis B virus as measured by loss of virus DNA. In the interferon treated group, three of the seven (43 percent) treated patients lost the hepatitis B virus, which is consistent with the remission rate published by other investigators.
 The results with Thymosin alpha 1 in the Italian study are similar to results published in Hepatology in 1991 by Mutchnick et al in which six of seven patients with chronic hepatitis B treated with Thymosin alpha 1 or a calf thymus extract containing Thymosin alpha 1 demonstrated loss of the hepatitis B virus.
 These preliminary results are part of a larger 70-patient, five- center, randomized clinical study evaluating the use of Thymosin alpha 1 in the treatment of hepatitis B that is currently being completed in Italy. The study is being sponsored by Sclavo, S.p.A., of Siena, Italy, which has licensed the rights in Italy to Thymosin alpha 1 from Alpha 1 Biomedicals. The drug used in these studies was manufactured by Alpha 1 Biomedicals. Sclavo believes that the results from the completed study will be submitted to the Italian Ministry of Health at the end of 1992 or very early in 1993 in support of the registration of Thymosin alpha 1 for treatment of chronic hepatitis B.
 Vincent F. Simmon, president and chief executive officer of Alpha 1 Biomedicals, stated, "This is the first independent confirmation of the Mutchnick study. Also, we are encouraged with the progress being made by Sclavo towards obtaining marketing approval in Italy for Thymosin alpha 1."
 Alpha 1 Biomedicals is conducting a double-blind, randomized, three-center clinical trial in the United States for Thymosin alpha 1 treatment of chronic hepatitis B. The results of the U.S. study are not expected to become available until the latter half of 1993.
 Alpha 1 Biomedicals, Inc., is a Washington-based company engaged in the development of pharmaceutical products for the treatment of human immune disorders.
 -0- 4/7/92
 /CONTACT: Judith A. Hautala, Ph.D., of Alpha 1 Biomedicals, 202-628-9898; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM) CO: Alpha 1 Biomedicals, Inc.; Sclavo, S.p.A. ST: District of Columbia IN: MTC SU:


GK-OS -- NY014 -- 5718 04/07/92 09:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:487
Previous Article:IDEX AGREES TO PURCHASE ASSETS OF PULSAFEEDER SUBSIDIARY OF EAGLE INDUSTRIES
Next Article:FORD IN OHIO - 1991


Related Articles
SCICLONE PHARMACEUTICALS TO USE NEW CLINICAL DATA CONFIRMING THYMOSIN ALPHA 1'S SUPERIOR EFFECTIVENESS IN TREATING HEPATITIS B
THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES PUBLICATION OF PRICE APPROVAL OF THYMOSIN ALPHA 1 IN ITALY
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES PRELIMINARY RESULTS OF CHRONIC HEPATITIS B CLINICAL TRIAL
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES
SCICLONE PHARMACEUTICALS REPORTS CONTINUED ENCOURAGING TREND IN TAIWAN CLINICAL TRIAL AND COMPLETION OF ANALYSIS OF U.S. CLINICAL TRIAL
ITALIAN RESEARCHERS REPORT PROMISING RESULTS IN PHASE III STUDY OF THYMOSIN ALPHA 1 AS IMMUNE SYSTEM ENHANCER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters